Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E
June 08, 2020 08:55 ET
|
Sarepta Therapeutics, Inc.
-- In post-treatment muscle biopsies, clinical trial participants in the high-dose cohort showed a dose-dependent increase in transduction and expression when compared with the low-dose cohort, with a...
Sarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
June 05, 2020 16:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, June 8, 2020...
Sarepta Therapeutics to Present at Upcoming Investor Conferences
June 02, 2020 17:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2020 18:27 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 29, 2020 that...
Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference
May 12, 2020 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases
May 11, 2020 07:00 ET
|
Sarepta Therapeutics, Inc.
-- Agreement leverages Sarepta’s leadership in gene therapy for neuromuscular and cardiovascular diseases and Dyno’s CapsidMap artificial intelligence platform to design AAV vectors -- CAMBRIDGE,...
Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments
May 06, 2020 16:05 ET
|
Sarepta Therapeutics, Inc.
– Net sales of $100.4 million, a 15% increase over same quarter of prior year – – $2.2 billion of cash on hand to drive clinical programs without distraction from COVID-19 pandemic – CAMBRIDGE,...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2020 18:52 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2020...
Sarepta Therapeutics to Announce First Quarter 2020 Financial Results and Recent Corporate Developments on May 6, 2020
April 29, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2020 financial...
Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19
April 28, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Company and the...